NRx Pharmaceuticals, Inc. (NRXP) Stock Ticker
NRXP right now
Market factors today
Unlock the full NRXP picture
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
NRXP stock facts
| Ticker symbol | NRXP |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $51.8M |
| CEO | Jonathan C. Javitt |
| Employees | 29 |
| Headquarters | Wilmington, DE, US |
| IPO date | 2017-12-04 |
| Website | www.nrxpharma.com |
What you can see for NRXP on Tickr
Live NRXP price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the NRXP report.
Rankings
FAQ
What is the ticker symbol for NRx Pharmaceuticals, Inc.?
The ticker symbol for NRx Pharmaceuticals, Inc. is NRXP, listed on the NASDAQ Global Market.
What is NRXP?
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company…